spravato fda news - Search News

FDA Approves ‘Spravato’ Nasal Spray

Medical News Today · 2h

FDA-approved nasal spray for severe depression can lead to remission

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.

UPI News on MSN · 5d

FDA approves Spravato, first monotherapy nasal spray to treat depression

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder,

Can a Nasal Spray Really Help Treat Depression? Here's What to Know About Spravato

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Johnson & Johnson's Spravato gains FDA nod to be used as a monotherapy

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...

J&J’s Spravato Makes Headway in Tough Depression Space With Monotherapy Approval

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

Hosted on MSN2d

FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with it

On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results